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Abstract Primary and secondary immunodepressive
conditions are associated with an increased incidence of
sebaceous tumors. Microsatellite instability (MSI) and lack
of expression of mismatch repair (MMR) proteins, typical
markers of Muir–Torre/Lynch heredo-familial settings, can
be recognized also in immunocompromised patients. We
aimed to carry on a systematic examination of clinical,
immunohistochemical, biomolecular features of sebaceous
tumors arising in immunocompromised and immunocom-
petent patients between 1986 and 2012. Microsatellite
screening, immunohistochemical analysis and genetic
testing were performed for hMLH1, hMSH2 and hMSH6.
Methylation status of MMR genes was checked in cases
with immunohistochemistry (IHC) loss of MMR proteins
expression and no germline mutations. Fifteen patients had
a personal history of visceral carcinomas fulfilling diag-
nostic criteria for Muir–Torre syndrome. In this cohort,
IHC analysis, MSI status and genetic testing were in
agreement, showing eight MSH2 and two MLH1 germline
mutations. Five patients were immunosuppressed and their
sebaceous tumors showed a lack of MSH2/MSH6 expres-
sion, although just one case with positive family history for
visceral cancer harbored a germline mutation. In immu-
nosuppressed patients, loss of IHC for MMR proteins is not
necessarily secondary to MMR germline mutations. IHC
false positives are probably due to epigenetic alterations.
MSI and lack of expression of MMR proteins can be rec-
ognized also in immunocompromised patients without
MMR germline mutations.
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Introduction
It is well known that primary and iatrogenic immunode-
pression is associated to an increased incidence of skin
tumors [1–3]. Among them, significantly higher incidence
rates of uncommon sebaceous adenomas and adenocarci-
nomas were significantly reported in immunosuppressed
compared to immunocompetent patients (30 vs. 6 %) [4].
The so-called Muir–Torre syndrome (MTS), a variant of
the Lynch syndrome (LS), is characterized by the presence
of early-onset sebaceous tumors and keratoacanthomas
associated to visceral malignancies. Tumors arising in
MTS or LS patients are featured by the presence of a
typical instability at microsatellite loci (MSI), which is
caused by germline mutations of the DNA mismatch repair
(MMR) genes MLH1, MSH2, MSH6, whose loss of
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expression can be tested through immunohistochemistry
(IHC) [5, 6]. Some primary and secondary immunode-
pressive conditions are associated to an increased incidence
of rare sebaceous tumors [7], in which, beyond the direct
pathogenic effect of oncogenic virus [8, 9], a role for
genetic aberrations has been hypothesized [10] and among
those for MSI and loss of IHC expression of MMR proteins
[8]. In immunodepressed individuals, however, the under-
lying gene alteration causing the loss of MMR proteins
expression at IHC is still poorly understood: so far, recent
case reports showed that immunodepression can unmask a
genetic predisposition linked to germline mutations whose
phenotypic silent characteristic is represented cancer
development [7, 11]. However, the genetic mechanism
determining MSI and/or loss of MMR expression in seba-
ceous tumors in the absence of a germline mutation could
be reconducted to a more general mechanism, like de novo
methylation of promoters, which has been postulated as a
major mechanism of inactivation of tumor suppressor
genes [12, 13].
In our single center study, we aimed to carry on sys-
tematic examination of clinical, immunohistochemical and
biomolecular features of cutaneous appendageal tumors
arising in immunocompromised and immunocompetent
patients between 1986 and 2012.
Methods
Ethics statement
This study was approved by the Ethical Committee of the
University Hospital of Modena, Italy, and was conducted
after informed written consent of enrolled patients.
Patients and tumor samples
From 1986 through 2012, a total of 142 sebaceous
tumors (embedded in paraffin) from 90 patients (54
males and 36 females) were retrospectively retrieved
from the archives of the Pathology Department of the
University of Modena. One hundred and eight lesions
were sebaceous adenomas and 34 were sebaceous car-
cinomas. A tumor was classified as sebaceous when
well-defined, enlarged, sebaceous lobules were present
that comprised fully mature sebocytes, frequently
demonstrating an attachment to the epidermis with
epidermal thinning. In sebaceous carcinomas, variably
atypical, polyhedral cells are present that are separated
from one another by fibro-vascular stroma, sometimes
with spread of pagetoid epithelial cells into the
epidermis.
Family history
Detailed family history was collected for each patient by
interviewing the patients and/or their relatives. Verification
of cancer occurrence among family members was obtained
in the majority of patients through clinical charts, patho-
logic records, or death certificates. Through the recon-
struction of the genealogic tree, 15 patients with MTS were
identified (10 males and 5 females).
Microsatellite analysis
For microsatellite analysis, DNA was extracted from
micro-dissected neoplastic and paired normal mucosa
specimens of dermatologic lesions and visceral malignan-
cies according to standard procedure. MSI was evaluated
with 5 microsatellite markers (BAT25, BAT26, BAT40,
D2S123, and D5S346) using a fluorescence-based poly-
merase chain reaction (PCR) method. DNA samples from
normal tissues and tumor tissues were amplified in a 10-lL
volume containing 30–50 ng of DNA; 5 ng of dye-labeled
forward and unlabeled reverse primers; 200 lm each of
deoxyguanine triphosphate, deoxythymidine triphosphate,
deoxyadinosine triphosphate, and deoxycytidine triphos-
phate; 1.5 mM MgCl2; 50 mMKCl; 10 mM Tris, pH 8.3;
and 0.3 U of Taq polymerase. All samples were run on a
CEQ 8000 sequencer and were analyzed using a fragment
analysis system (Beckman Coulter). MSI-positive tumors
were defined as tumors in which instability was detected in
at least two microsatellite loci [14].
Immunohistochemistry
Immunohistochemical analysis of MLH1, MSH2 and
MSH6 proteins were carried out on paraffin-embedded
tumor samples. Immunoperoxidase staining using diam-
inobenzidine as a chromogen was run with the NEX-ES
Automatic Staining System (Ventana, Strasbourg, France).
The mouse monoclonal antibodies used were anti-MSH6
(clone 44; Transduction Laboratories) at 1:2,000 dilution,
anti-MLH1 (G168-15; Pharmingen) at 1:40 dilution, and
anti-MSH2 (G129-1129; Pharmingen) at 1:40 dilution.
Nuclei were counterstained with haematoxylin. Adjacent
normal tissues from each sample served as positive
controls.
Mutational analysis and methylation status analysis
of MMR gene promoter regions
Germline mutations in hMLH1, hMSH2 and hMSH6 were
studied by single-strand conformation polymorphism
(SSCP) on DNA derived from blood leukocytes. Samples
that showed an altered SSCP mobility pattern were
G. Ponti et al.
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sequenced by means of the Sequenase PCR product
sequencing kit (Amersham Life Science, Buckinghamshire,
United Kingdom) using a Beckman sequencer (model CEQ
8000).
The probe mix contains thirty-eight probe sequences of
which 22 different probes for MMR genes containing one
or two digestion sites for the methylation sensitive HhaI
enzyme. The remains probes are reference ones that are not
influenced by HhaI digestion. In particular, the ME011 kit
includes three testing probes for MSH2 gene, located in the
promoter region and in exon 1: the first one is located at
nucleotide 269 before ATG, the second one is located at
193 nucleotide before ATG and the last one is at nucleotide
124 after ATG.
In the present study, each experiment was carried out in
duplicate, according to the manufacturer’s instructions
(http://www.mrc-holland.com) and normal DNA speci-
mens derived from lymphocytes from healthy controls
were included in every assay.
Briefly, for each MS-MLPA reaction, 100 ng of DNA
was used. PCR products were run onto an ABI 310 capil-
lary sequencer and analyzed using Gene Mapper v. 4.0
analysis software (Applied Biosystems, Foster City, CA).
Data analysis for evaluating methylation status, has been
performed with two different methods: an excel spread-
sheet and the Coffalyser.Net software.
A dosage ratio of 0.15 or higher, corresponding to 15 %
of methylated DNA, was applicated to indicate promoter
methylation.
Methylation analysis was performed by the methylation-
specific multiplex ligation-dependent probe amplification
(MS-MLPA) assay that is a modification of the MLPA
technique. It allows the detection of both copy number
changes and unusual methylation levels of different
sequences in specific regions in one simple reaction.
The MS-MLPA ME011 kit from MRC-HOLLAND
company was employed to detect aberrant CpG Island
methylation in the MMR promoter region genes.
In general, the MS-MLPA protocol is very similar to the
standard MLPA method, except that each MS-MLPA reaction
generates two samples: one undigested sample for copy
number detection and one digested sample for methylation
detection. The MS-MLPA procedure can be divided into five
steps: DNA denaturation and hybridization of MLPA probes;
ligation and digestion; PCR; separation of amplification pro-
ducts by capillary electrophoresis and data analysis.
MS-MLPA probes for methylation detection resemble
other MLPA probes, except that their target sequence
contains the restriction site of the methylation-sensitive
endonuclease HhaI. So, not all the probes provide infor-
mation on methylation status but only the probes that
contain a sequence recognized by the methylation-sensitive
restriction enzyme HhaI.
After hybridization, the reaction is split into two tubes:
one tube is processed as a standard MLPA reaction, pro-
viding information on copy number changes. The other is
incubated with the HhaI endonuclease meanwhile hybrid-
ized probes are ligated. Hybrids of probes and unmethy-
lated sample DNA are digested by the HhaI enzyme that
digests unmethylated DNA from the middle of GCGC
sequences but leaves methylated sites intact.
Digested probes cannot be amplified exponentially
during PCR and hence will not produce a signal during
capillary electrophoresis. In contrast, if the sample DNA is
methylated, the DNA-probe hybrids are protected against
HhaI digestion and the ligated probes will generate a peak.
Results
Clinical features
Between 1986 and 2012, 142 sebaceous tumors of 90
patients (54 males and 36 females) were collected. More
specifically, 108 were sebaceous adenomas and 34 seba-
ceous carcinomas.
Fifteen patients had a history of intestinal or other vis-
ceral carcinomas, thus fulfilling the criteria for a clinical
diagnosis of MTS (10 males and 5 females) (Table 1).
Among the 75 apparently sporadic patients only one
(patient 1) had a family history evocative of LS (Fig. 1).
In the MTS group, there were 60 skin lesions, including
48 sebaceous adenomas and 12 sebaceous carcinomas. The
average age at onset of the first skin malignancy was
57.87 years (range 38–89 years) compared with
69.35 years (range 45–91 years) in the sporadic group.
In patients with MTS, skin lesions were often multiple,
synchronous, or metachronous, and were located predom-
inantly in the head and neck.
In six patients with MTS, sebaceous lesions occurred as
the first neoplasm while in the remaining nine patients,
these lesions developed after an internal malignancy.
Among the 15 MTS probands, 12 colorectal carcinomas
and 3 gastric carcinomas were found.
The average age at onset of the first visceral malignancy
was 56.27 years. In addition to skin and visceral malig-
nancies, the tumor spectrum included one kidney carci-
noma, one carcinoma of the renal pelvis, one uterus
carcinoma and one breast tumor. Finally, in two MTS
probands, psoriatic arthropathy was diagnosed. Among
first-degree relatives, colon, lung, brain, breast, pancreas,
kidney, bladder, gastric, liver, uterus and ovary carcino-
mas, non-Hodgkin lymphoma and laryngeal tumors were
detected.
Five apparently sporadic patients with the only seba-
ceous tumors were considered immunosuppressed: three
Mismatch repair proteins in sebaceous tumors of immunocompromised patients
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patients received a transplant (two had kidney transplan-
tation and one heart transplantation) whereas the remaining
two were immunocompromised because of cancer and
iatrogenic causes. All of them developed sebaceous tumors
after becoming immunosuppressed.
Patient 1
Of the two renal transplant recipients, (RTR) the first
patient, RTR1 underwent the surgical intervention at the
age of 49, and developed 5 sebaceous adenomas, four
located on the face and one in the lumbar region. The first
sebaceous adenoma, of the face, was excised at the age of
52. He was diagnosed of a colonic adenoma at the age of
36. After the transplant, he developed a basal cell carci-
noma on the nose and one keratoacanthoma on the face. All
of his sebaceous tumors were adenomas and shared the
same molecular markers, IHC MMR proteins expression,
mutation and methylation. Among his relatives, his sister
had a positive personal history of colon cancer discovered
at the age of 65, while another sister and a niece were
diagnosed of endometrial cancer at the age of 54 and 50
respectively. The patient was under immunosuppressive
treatment with prednisone (Deltacortene) and tacrolimus
(Prograf) (Fig. 1). However, his family members were not
affected by cutaneous sebaceous tumors.
Patient 2
RTR2 underwent kidney transplant in 1998 at the age of
45, and developed a sebaceous adenoma of the left lower
eyelid at the age of 58. Later on, two more sebaceous
adenomas of the face were found. The patient has not been
diagnosed of any visceral malignancies so far, and he is
affected by Berger syndrome. In his family, two sisters had
uterine fibromas, and one of them also had colon cancer of
the sigmoid tract with liver metastasis; moreover, one
maternal uncle had colon cancer. The patient was under
immunosuppressive treatment with cyclosporine A and
switched to prednisone (Deltacortene) and Tacrolimus
(Prograf) in 2012.
Patient 3
Patient 3, a heart transplant recipient (HTR) underwent
heart transplant at the age of 63; he developed a sebaceous
Fig. 1 A Muir–Torre syndrome family (renal transplant recipient Patient 1 under immunosuppressive treatment for and gene-carrier of MSH2
germline mutation c.1216C[T)
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adenoma of the left cheek 1 year later. He was also diag-
nosed of one ulcerated basal cell carcinoma (BCC) of the
neck. The patient’s personal and family history was neg-
ative for visceral and skin neoplasms. He was always
treated with cyclosporine but denied his consent to genetic
testing.
Patient 4
The patient, male, was diagnosed of prostate carcinoma at
the age of 55, and non-Hodgkin lymphoma at the age of 67,
that was treated with chemotherapy following the R-CHOP
scheme. Some months after chemotherapy he developed a
sebaceous adenoma of the left cheek (at the age of 68) and
a superficial BCC of the face. His family history is negative
for either skin or visceral tumors.
Patient 5
Patient 5, a female patient, had a uterine leiomyoma at the
age of 26; she was also diagnosed a tubulo-villous ade-
nomas with high-grade dysplasia in the colon at the age 61.
Because of her hyperthyroidism, she was treated with
radioactive iodine followed by methimazole. She devel-
oped a sebaceous carcinoma of the lumbar region at the age
of 59. Concerning her family history, her father died of
lung cancer while her mother died of brain cancer,
respectively.
MSI and IHC features
For all patients, we examined the sebaceous skin tumors for
microsatellite status and immunohistochemical expression
of the MLH1, MSH2, and MSH6 proteins. The MTS skin
lesions showed microsatellite instability (MSI) and loss of
MMR expression at the IHC in 13 probands: in 10 cases the
lack of expression was related to the MSH2/MSH6 pro-
teins, whereas absence of MLH1 was evident in 3 pro-
bands. In two patients the results could not be obtained as
the patients died.
The IHC of the sebaceous tumors belonging to the
immunocompromised patients showed lack of expression
for MSH2/MSH6 in four cases and MLH1 in one (Table 2).
No loss of IHC expression of MLH1 or MSH2/MSH6
proteins were seen in the sebaceous neoplasms of the other
70 sporadic patients.
MMR sequencing
Germline mutation in MSH2 and MLH1 genes were iden-
tified in nine MTS probands (Table 1). One MTS patient
(Patient 1) denied his consent for blood sampling and five
patients were deceased at the time of our investigation.
In the cohort of five immunosuppressed patients, for
which IHC showed positivity, direct sequencing for MMR
genes was performed for patient RTR1, RTR2, patient 4 and
patient 5 (Table 2). One constitutional mutation of the MSH2
gene has been detected [exon 7, c.1216C[T(p.Arg406x)
codon 406] (Table 2). None of the patients analyzed had the
promoter hypermethylation of the MSH2 gene. All the other
sporadic lesions were MSI negative and showed expression
of all MMR proteins.
Discussion
The examination of clinical, immunohistochemical and
biomolecular features of sebaceous tumor patients high-
lighted that, despite the crucial role of IHC for MMR genes
in the selection and identification of MTS, the genetic
counselor should consider the possibility of a IHC-bias
related to the IHC findings showing loss of MMR proteins
expression in sebaceous tumors in both MTS-associated
and immunodepressive-related lesions can not be ruled out.
This false positivity could lead to an overestimation of
‘‘true’’ MTS since phenocopies (disease subtypes or non-
genetic causes of disease) could be mistakenly regarded as
MTS and thus the patients subjected to useless direct gene
sequencing.
Despite the important correlation between MSI and
MMR proteins deficiency, it is generally known that the
lacking expression of MSH2 and MLH1 might also be
unrelated to germline mutations [15, 16]. Moreover, in
contrast to colorectal tumors in the context of LS, char-
acterized by clear cut guidelines [17], for determining MSI
phenotype and IHC status of MMR proteins, in sebaceous
skin tumors the precise modalities for the recognition of
MTS are not well delineated, although a huge number of
data are available in support of the usefulness, sensitivity
and specificity of the IHC of the MMR genes [18–23].
A recent study on the role of the molecular screening of
sebaceous adenomas and carcinomas in the diagnosis of LS
highlighted the limits of the revised Bethesda guidelines
and gave a hint on the possible alternative approaches to
the identification of the syndrome, based on other tumors of
the syndromic spectrum (i.e. endometrial cancer) [24]. For
sebaceous tumors, however, there are no clear data on their
role as a screening tool in the ascertainment of MTS.
Even if it is well known that immunodepression can
unmask a genetic predisposition linked to germline muta-
tions [7, 11] screening all immunocompromised patients
with sebaceous tumors for MSI, IHC and MMR genetic
testing may result in a low rate of MTS finding and in the
absence of personal or family history clearly suggestive for
LS/MTS, additional features should be evaluated to esti-
mate the risk of a genetic syndrome [25–27]. In particular,
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some issues focused on the value of IHC for MMR genes as
screening procedure for sebaceous neoplasms in immuno-
suppressed patients without positive personal and/or family
history of visceral cancers, that do not fulfill the clinical
criteria for MTS. However, the detection of MSH2 germ-
line mutation in our transplanted patient presenting a
‘‘sebaceous tumors only’’ phenotype (Fig. 1) supports the
hypothesis that immunosuppression may unmask systemic
MTS mutations. This experience suggests the effectiveness
of testing the mutational status of MMR genes also in
immunocompromised patients with cutaneous phenotype
MTS compatible and IHC showing the loss of MMR pro-
teins expression, particularly when there is a positive
family history for visceral malignancies. This could result
in earlier recognition of the MMR gene mutation carrier
patients at high risk of developing visceral malignancies, as
in the case of Patient 1.
Immunocompromised patients with IHC showing loss of
MMR proteins expression in their sebaceous neoplasms
and neither germline mutations nor visceral malignancies
are much more intriguing from the point of view of path-
ogenesis, clinical management and follow-up. It is possible
that sebaceous tumors carrying IHC loss of MMR proteins
expression in the absence of a germline mutation are
related to other mechanisms.
Although our MMR gene promoter methylation in
sebaceous tumors with loss of MMR proteins at IHC did not
lead to positive results, it is necessary to ascertain the
effective limits of the technique used. MS-MLPA kit con-
tains three probes for MSH2 promoter encompassing the
main CpG-rich regions but not the entire gene. Moreover,
mosaicism is a common facet of epimutations [28, 29] and
mosaic epimutation shows variable degrees of allelic
methylation and transcriptional silencing and/or tissue dis-
tribution. This semi-quantitative technique could lead to an
underestimation of hypermethylation of further specific
regions not investigated with this method and it could not
detect low-levels of hypermethylation.
Further speculative hypothesis that can somehow
explain IHC positivity in the absence of germline muta-
tions are linked to the effects of some immunosuppressive
drugs. Immunosuppressors could interact with MMR pro-
teins causing a mutator phenotype and MSI, such as skin
cancer. It has been hypothesized that immunosuppressive
drugs, in particular azathioprine, may select cells hosting a
MMR deficit, as a mechanism of evading its cytotoxic
Table 2 Clinical, immunohistochemical and biomolecular features of immunosupressed patients
Patient
number
Sex Age
at
first
skin
lesion
No. of
skin
lesions
Skin
lesion
histology
Site Visceral
tumor
in the
proband
(age in
years)
Other tumors
in
the proband
(age in
years)
Tumors in
the family
(age
in years)
IHC
analysis
(loss
of)
Immunological
status
and therapy
Mutation and
methylation
analysis
1 M 52 5 SEB AD Head,
back
– – Colon
(65),
uterus
(54),
uterus
(50)
MSH2/
MSH6
Glomerulonephritis
(35), kidney
transplant (49);
prednisone,
tacrolimus
MSH2
mutation
[exon 7,
c.1216C[T
(p.Arg406x)
codon 406]
2 M 58 3 SEB AD Head – – Colon
(41),
colon
(44),
uterus
(38),
uterus
(46)
MSH2/
MSH6
Berger’s disease
(27), kidney
transplant (45);
prednisone,
tacrolimus
Negative
3 M 64 1 SEB AD Head – – – MSH2/
MSH6
Heart transplant
(63); cyclosporine
A
Test refused
4 M 68 1 SEB AD Head Prostate
(55)
Non-
Hodgkin’s
lymphoma
(67)
– MSH2/
MSH6
Chemotherapy (R-
CHOP) (67)
Negative
5 F 59 1 SEB CA Back Left
colon
(61)
Uterus (26) Lung (86),
brain
(59)
MLH1 Radioactive iodine
and methimazole
(30)
Negative
M male, F female, SEB CA sebaceous carcinoma, SEB AD sebaceous adenoma, IHC immunohistochemistry
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effects [7]. Moreover, it is also evident that the type,
duration and intensity of the iatrogenic immunodepression
can influence the singular susceptibility to skin tumors [30,
31]. However, when we consider the common increased
predisposition to the development of sebaceous neoplasms
with IHC loss of MMR proteins expression in HIV positive
individual, it is possible to infer that the above-discussed
clinical entity is caused by the immunosuppressive state
itself and is not bound to the type of immunosuppressive
agents [32].
Although the clinical diagnosis of MTS requires the
association of at least one sebaceous skin tumor and/or
keratoacanthoma together with a visceral tumor, we must
take into account the cases MTS ascertained through
sebaceous tumors, in which the clinical tumor spectrum of
MTS/LS is not fully expressed in the proband, but only
observed in the family history. In order to perform a correct
clinical diagnosis of MTS, it is thus necessary to consider
the pathological, personal and familial history; there are, in
fact, different and complex disease settings as well as
sporadic and/or iatrogenic factors potentially responsible
for the final clinical MTS phenotype.
In particular, although considering the hypothesis of an
unmasked phenomenon while evaluating sebaceous neo-
plasms in immunocompromised patients, it is necessary to
include a potential bias. The latter is linked to the existence
of immunocompromised patients with IHC loss of
expression of MMR proteins that act as clinical pheno-
copies and lead to overestimating the potential number of
true MTS cases. On the other hand, the analysis of MMR
proteins’ expression can be considered an efficacious tool,
even in immunosuppressed patients with no visceral
malignancies but who bear the brunt of a positive family
history of cancer.
Future studies focusing on the proteomic profiles of the
MMR proteins could help us clarify the role of the epige-
netic alterations of the proteins. It is also important to
elucidate the role of methylation processes in the expres-
sion of MSH2/MSH6 proteins: those cannot be reasonably
considered of minor importance with respect to the MLH1
protein, whose silencing mechanisms are already known.
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